Development of 153Sm-DTPA-rituximab for radioimmunotherapy

• Autorzy: Bahrami-Samani A. , Ghannadi-Maragheh M. , Jalilian A. R. , Yousefnia H. , Garousi J. , Moradkhani S.
• Języki publikacji: EN

Abstrakty

EN

Combining beta-particle effect with therapeutic properties of anti-CD20 monoclonal antibody in lymphomas, Mabthera™ (rituximab) was targeted in this study. The antibody was labeled with 153Sm-samarium chloride (185 MBq) after conjugation with freshly prepared ccDTPA. Conjugated-rituximab was obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH = 7.8) to a glass tube precoated with freshly prepared ccDTPA (0.01–0.1 mg) at 25 degrees centigrade. Sm-153 chloride was obtained by a thermal neutron flux (5 × 1013 nźcm–2źs–1) of an enriched 152Sm2O3 sample, dissolved in acidic media. Radiolabeling was performed in one hour by the addition of DTPA-rituximab conjugate at room temperature. Radiochemical purity of 96% (ITLC) and 98% (HPLC) were obtained for the final radioimmunoconjugate (specific activity = 120 TBq/mmol). The final isotonic 153Sm-rituximab complex was checked by gel electrophoresis for protein integrity retention. Biodistribution studies in normal rats were performed to determine radioimmunoconjugate distribution up to 24 h. SPECT images were also obtained using 103 keV photons up to 48 h.

Słowa kluczowe

EN

radiopharmaceutical; samarium-153; rituximab; targeted therapy; SPECT

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2009
• Tom: Vol. 54, No. 4
• Strony: 271--277
• Opis fizyczny: Bibliogr. 21 poz., rys.

Twórcy

autor

Bahrami-Samani A.

autor

Ghannadi-Maragheh M.

autor

Jalilian A. R.

autor

Yousefnia H.

autor

Garousi J.

autor

Moradkhani S.

• Faculty of Nuclear Engineering and Physics, Amirkabir University of Technology, P. O. Box 15875-4413, Tehran, Iran,

Bibliografia

• 1. Awang MB, Hardy JG, Davis SS, Pimm MV, Parry SJ, Wilding IR (1994) Evaluation of 153Sm-diethylenetri-aminepentaacetic acid for radiolabelling of pharmaceutical dosage forms by neutron activation. Nucl Med Biol 21:905–909
• 2. Dietlein M, Pels H, Schulz H et al. (2005) Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 74:348–352
• 3. Eary JF, Press OW, Badger CC et al. (1990) Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257–1268
• 4. Fani MS, Vranjes SC, Archimandritis S, Potamianos S, Xanthopoulos P, Bouziotis AD (2002) Labeling of monoclonal antibodies with 153Sm for potential use in radioimmunotherapy. Appl Radiat Isot 57:665–674
• 5. Ferro-Flores G, De Mara Ramrez F, Tendilla JI et al. (1999) Preparation and pharmacokinetics of samarium(III)-153--labeled DTPA-bis-biotin. Characterization and theoretical studies of the samarium(III)-152, conjugate. Bioconjugate Chem 10:726–734
• 6. Gmeiner Stopar T, Fettich J, Zver S et al. (2009) 99mTc- -labelled rituximab, a new non-Hodgkin’s lymphoma imaging agent: first clinical experience. Nucl Med Commun 29:1059–1065
• 7. Green MA, Welch MJ (1989) Gallium radiopharmaceutical chemistry. Nucl Med Biol 16:435–448
• 8. Hnatowich DJ, Layne WW, Child RL et al. (1983) Radioactive labeling of antibody: a simple and efficient metod. Science 220:613–615
• 9. http://www.pathologyoutlines.com/lymphoma.html
• 10. Jalilian AR, Mirsadeghi L, Haji-Hosseini R, Khorami A (2008) Preparation, quality control and biodistribution studies of [67Ga]-DOTA-anti-CD20. Radiochim Acta 96:167–174
• 11. Jalilian AR, Sardari D, Kia L et al. (2008) Preparation, quality control and biodistribution studies of two [111In]--rituximab immunoconjugates. Sci Pharm 76:151–170
• 12. Knox SJ, Levy R, Miller RA et al. (1990) Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50:4935–4940
• 13. Kyle RA, Gertz MA, Greipp PR et al. (1999) Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 93:1062–1066
• 14. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature 227:680–685
• 15. Pandey U, Mukherjee A, Sarma HD, Das T, Pillai MRA, Venkatesha M (2002) Evaluation of 90Y-DTPA and 90Y--DOTA for potential application in intra-vascular radionuclide therapy. Appl Radiat Isot 57:313–318
• 16. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J (2001) Immunotherapy of non-Hodgkin’s lymphomas. Hematology – Am Soc Hematol Educ Program Book: 221–240
• 17. Rituxan® (Roche) pamphlet, P.1, chapter B. CCO Formulary, Revised 2004/2005
• 18. Rizvi SMA, Henniker AJ, Goozee G, Allen BJ (2002) In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leukemia Res 26:37–43
• 19. Smith-Jones P, Solit DB, Akhurst T, Afroze F, Rosen M, Larsen SM (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22;6:701–706
• 20. Sodoyez J, Sodoyez-Goffaux F, von Frenckell R, De Vos CJ, Treves S, Kahn CR (1985) Differing effect of antiinsulin serum and antiinsulin receptor serum on 123I-insulin metabolism in rats. J Clin Invest 75:1455–1462
• 21. Witzig TE, White CA, Wiseman GA et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non- -Hodgkin’s lymphoma. J Clin Oncol 17:3793–3803